30 Participants Needed

Cancer Vaccine for Chronic Lymphocytic Leukemia

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial studies a special vaccine made from a patient's own cancer cells and an immune booster to treat chronic lymphocytic leukemia. It targets patients who have not been treated before, aiming to help their immune system recognize and destroy cancer cells.

Research Team

SM

Shuo Ma, MD, PhD

Principal Investigator

Northwestern University

Eligibility Criteria

Adults with untreated chronic lymphocytic leukemia (CLL) showing disease progression but not severe enough to require immediate treatment. Participants must have a certain level of white blood cells, be in good physical condition, and have normal kidney and liver function. Women who can bear children and sexually active men must use contraception. Those with other cancers, immune diseases, or infections that could affect the trial are excluded.

Inclusion Criteria

Patients must have adequate renal and hepatic function:
Serum creatinine less than or equal to 2.0 mg/deciliter (dL)
Total Bilirubin less than or equal to 2.0 mg/dL
See 12 more

Exclusion Criteria

Patients who meet any of the NCI Working Group criteria to initiate treatment for CLL are NOT eligible for participation
Patients who have had or are currently receiving any treatment for CLL, including chemotherapy, corticosteroids, biologic therapy, or immunotherapy are NOT eligible for participation.
Patient who had a stage 1 solid tumor which has been adequately treated with curative intent, and has been in remission for more than 1 year.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months

15 weeks
5 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 year
Monthly for 3 months, then every 3 months

Treatment Details

Interventions

  • Oncoquest-CLL vaccine
Trial Overview The trial is testing a new vaccine therapy called Oncoquest-CLL for CLL patients. It uses liposomes with cancer cell extracts and interleukin-2 to potentially stimulate the body's immune system to attack leukemia cells.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Oncoquest-CLL vaccine treatmentExperimental Treatment1 Intervention
Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.

Find a Clinic Near You

Who Is Running the Clinical Trial?

XEME Biopharma Inc.

Lead Sponsor

Trials
2
Recruited
60+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security